Stock Analiz

CorMedix Inc. CRMD

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$4.66Market cap $371M
Open the interactive analysis →

CorMedix Inc. (CRMD) is a healthcare company listed in the US with a market value of about $371M. In the twelve months to September 30, 2026 it had revenue of $412M and net income of $64M, a net margin of 15.5%.

Its overall Stock Analiz score is 3.0 out of 5 (average). The strongest part is financial health (5/5); the weakest is shareholder returns (1/5).

Key numbers: a P/E of 7.3, a price to free cash flow of 1.2, 5-year revenue growth of 320% a year, a 5-year average ROIC of -30%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 65% below the current price.

About CorMedix

CorMedix is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $189274 in 2014 to $312M in 2025, growth of about 96.1% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 99% over three years (dilution for shareholders). It spends 6% of revenue on research and development.

Score: 3.0 / 5

Value3/5
Future growth4/5
Track record2/5
Financial health5/5
Shareholder returns1/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year

Checks not passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%
  • Profitable 5 years in a row
  • Pays a dividend
  • Share count down over 3 years (buybacks)

Valuation

P/E (TTM)7.3
Forward P/E—
P/FCF1.2
P/S0.9
P/B0.8
EV/EBITDA0.1
PEG—
Dividend yield0.00%
FCF yield83.1%
Shareholder yield0.0%
Intrinsic value vs. price−65%

Growth and quality

Revenue growth (1 yr)617.0%
Revenue growth (5 yrs, per year)319.8%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-15043.4%
ROIC (5-yr avg.)-29.6%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$412M$312M$43M—$65408$190936$239231$283266$429797$329327$224105
Net income$64M$163M-$18M-$46M-$30M-$28M-$22M-$16M-$27M-$33M-$25M
Free cash flow$308M$173M-$51M-$39M-$25M-$23M-$22M-$15M-$24M-$29M-$22M
EPS (diluted)$0.64$2.04$-0.30$-909.99$-739.99$-749.99$-769.99$-1799.99$-1509.99$-2999.98$-3249.00
Net margin15.5%52.3%-41.2%—-45409.9%-14774.7%-9207.7%-5801.3%-6242.4%-10023.4%-10996.5%
ROIC—29.0%-24.3%-54.6%-53.8%-44.2%-48.7%-67.9%-430.1%-361.6%-109.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 5 analysts is $13.80, 196% above the current price; targets range from $12.00 to $17.00; the consensus rating is “Buy”; expected EPS is $0.43 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is CorMedix’s P/E ratio?

About 7.3, based on the last twelve months of diluted earnings per share.

Is CorMedix stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 65% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does CorMedix pay a dividend?

Not currently.

Is CorMedix a good stock to buy?

We do not give buy or sell advice. CorMedix scores 3.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.